ArticleBMC oral health2026
Tubulin-tyrosine ligase-like protein 12(TTLL12): elevated expression in oral squamous cell carcinoma and its clinical prognostic implications.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe aim of the present study was to investigate the expression of tubulin-tyrosine ligase-like protein 12 (TTLL12) in oral squamous cell carcinoma (OSCC) and to explore its potential associations with clinicopathological characteristics and patient prognosis.
methodsA total of 162 OSCC tissue samples and 30 adjacent normal tissue samples were collected from patients who underwent surgical resection at the First Affiliated Hospital of Chongqing Medical University between May 2014 and December 2018. Paraffin sections were prepared, and TTLL12 expression was detected via immunohistochemistry (IHC). The data were analyzed using SPSS 24.0 software.
resultsImmunohistochemical analysis revealed that TTLL12 expression was significantly higher in OSCC tissues than in normal controls. High TTLL12 expression was significantly correlated with increased tumor size, advanced clinical stage, cervical lymph node metastasis, and risk of new distant metastasis during the follow-up period (P < 0.05). Multivariate Cox regression analysis revealed that TTLL12 expression was an independent prognostic factor for OSCC patient survival (P = 0.035). Moreover, patients with high TTLL12 expression had significantly shorter overall survival (OS) times than those with low TTLL12 expression (P < 0.001).
conclusionsElevated TTLL12 expression is associated with enhanced tumor growth and metastasis in OSCC, leading to poor prognosis. These findings suggest that TTLL12 is a potential biomarker for prognostic assessment in patients with OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.